J. Legos

发表

Inhibition of p38 mitogen‐activated protein kinase provides neuroprotection in cerebral focal ischemia

S. Kassis, John C. Lee, A. A. Parsons, 2001, Medicinal research reviews.

SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.

S. Kassis, John C. Lee, J. Adams, 2001, The Journal of pharmacology and experimental therapeutics.

SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia

A. A. Parsons, F. Barone, J. Legos, 2001, Brain Research.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The New England journal of medicine.

The selective p 38 inhibitor SB-239063 protects primary neurons from 2 mild to moderate excitotoxic injury 3

A. A. Parsons, S. Skaper, F. Barone, 2002 .

The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury.

A. A. Parsons, S. Skaper, F. Barone, 2002, European journal of pharmacology.

Quantitative changes in interleukin proteins following focal stroke in the rat

A. A. Parsons, F. Barone, J. Legos, 2000, Neuroscience Letters.

Programmable microchip monitoring of post-stroke pyrexia: effects of aspirin and paracetamol on temperature and infarct size in the rat

A. Mangoni, A. A. Parsons, F. Barone, 2002, Journal of Neuroscience Methods.

1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM).

A. Hauschild, C. Blank, V. Chiarion Sileni, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2016 .

Selective CETP Inhibition and PPARα Agonism Increase HDL Cholesterol and Reduce LDL Cholesterol in Human ApoB100/Human CETP Transgenic Mice

F. Barone, J. Legos, M. McVey, 2010, Journal of cardiovascular pharmacology and therapeutics.

LEX032, a novel recombinant serpin, protects the brain after transient focal ischemia.

J. Legos, R. Tuma, Michael Weaver, 2002, Microvascular research.

Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.

H. Sarau, J. Foley, F. Barone, 2002, The Journal of pharmacology and experimental therapeutics.

Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.

H. Sarau, J. Foley, F. Barone, 2000, The Journal of pharmacology and experimental therapeutics.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

J. Utikal, A. Hauschild, D. Schadendorf, 2015, The Lancet.

M2 receptors in genito-urinary smooth muscle pathology.

W. Young, J. Legos, A. Braverman, 1999, Life sciences.

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2017, The New England journal of medicine.

Stroke Genomics: Approaches to Identify, Validate, and Understand Ischemic Stroke Gene Expression

S. Bates, A. A. Parsons, F. Barone, 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Caspase 3 activation is essential for neuroprotection in preconditioning

F. Barone, J. Legos, J. Erhardt, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

Matthew Wongchenko, Jeffrey E Gershenwald, Lauren E Haydu, 2018, The Lancet. Oncology.

Tonicity of Resuscitative Fluids Influences Outcome after Spinal Cord Injury

J. Legos, R. Tuma, W. Young, 2001, Neurosurgery.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The Lancet. Oncology.

Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms.

K. King, J. Legos, Diptee A. Kulkarni, 2016, Pharmacogenomics.

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, Clinical Cancer Research.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

A. Hauschild, D. Schadendorf, K. Flaherty, 2017, European journal of cancer.

LBA4_PRCOMBI-V: A RANDOMISED, OPEN-LABEL, PHASE III STUDY COMPARING THE COMBINATION OF DABRAFENIB (D) AND TRAMETINIB (T) WITH VEMURAFENIB (V) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH UNRESECTABLE OR METASTATIC BRAF V600E/K MUTATION-POSITIVE CUTANEOUS MELANOMA

A. Hauschild, D. Schadendorf, R. Dummer, 2014 .

SB 234551 selective ETA receptor antagonism: Perfusion/Diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection

R. Bentley, A. A. Parsons, F. Barone, 2008, Experimental Neurology.

Inhibition of Phosphodiesterase Type 4 Decreases Stress-Induced Defecation in Rats and Mice

Hideo Kikkawa, F. Barone, H. Kikkawa, 2007, Pharmacology.

Caspase inhibitors as neuroprotective agents

J. Legos, J. Erhardt, Dennis Lee, 2001, Expert opinion on emerging drugs.

Acute stroke therapy: translating preclinical neuroprotection to therapeutic reality.

A. A. Parsons, F. Barone, E. Irving, 2000, Current opinion in investigational drugs.

Non-surgical management of spinal cord injury

W. Young, J. Legos, J. Gopez, 2002, Expert opinion on investigational drugs.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

J. Utikal, A. Hauschild, D. Schadendorf, 2019 .

Selective PPARδ agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study

S. Sarkar, J. Legos, S. Lenhard, 2007 .

LIPID METABOLISM WITHOUT ALTERING MITOCHONDRIAL ENERGY COUPLING : AN IN VIVO MAGNETIC RESONANCE SPECTROSCOPY STUDY

S. Sarkar, J. Legos, S. Lenhard, 2007 .

Expression of PEP‐19 inhibits apoptosis in PC12 cells

J. Legos, J. Erhardt, R. Johanson, 2000, Neuroreport.

Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study.

S. Sarkar, J. Legos, S. Lenhard, 2007, American journal of physiology. Endocrinology and metabolism.

Inhibition of p38 mitogen‐activated protein kinase provides neuroprotection in cerebral focal ischemia

S. Kassis, John C. Lee, A. A. Parsons, 2001, Medicinal research reviews.

Pharmacological interventions for stroke: failures and future

F. Barone, J. Legos, R. Tuma, 2002, Expert opinion on investigational drugs.

Abstract PR06: Phase 1b dose-escalation study of trametinib (MEKi) plus palbociclib (CDK4/6i) in patients with advanced solid tumors

R. Sullivan, K. Flaherty, J. Sosman, 2015 .

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, Clinical Cancer Research.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, The New England journal of medicine.

Coadministration of Methylprednisolone with Hypertonic Saline Solution Improves Overall Neurological Function and Survival Rates in a Chronic Model of Spinal Cord Injury

J. Legos, R. Tuma, W. Young, 2001, Neurosurgery.

Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration.

F. Barone, J. Legos, 2003, Current opinion in investigational drugs.